Home > Insider Trading > Filing (0001140361-11-048592)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184149	W Jonathan Ayers	One Idexx Drive Westbrook ME 04092	Chairman, President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-10-04	20,000	$12.60	317,697	No	4	M	Direct
Common Stock	Disposition	2011-10-04	9,500	$64.21	308,197	No	4	S	Direct
Common Stock	Disposition	2011-10-04	5,500	$64.59	302,697	No	4	S	Direct
Common Stock	Acquisiton	2011-10-05	20,000	$12.60	322,697	No	4	M	Direct
Common Stock	Disposition	2011-10-05	14,597	$66.12	308,100	No	4	S	Direct
Common Stock	Disposition	2011-10-05	403	$66.74	307,697	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-10-04	20,000	$0.00	20,000	$12.60
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-10-05	20,000	$0.00	20,000	$12.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,320		2012-01-28	No	4	M	Direct
80,320		2012-01-28	No	4	M	Direct

Footnotes

Includes 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2011.
The reported sale above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/03/2011.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $63.88 to $64.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.00 to $65.43, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $65.66 to $66.57, inclusive.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $66.69 to $66.75, inclusive.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (01/28/2003) of the date of grant.